Synthego - CRISPR Nuclease
Navigating the SpCas9 IP landscape for a CRISPR therapeutic is challenging, often resulting in delays in development. To accelerate the next generation of CRISPR-based therapeutic development by making CRISPR more accessible, we introduce our novel high-fidelity nuclease, hfCas12Max. Engineered from the CRISPR Cas12i nuclease to enable broad PAM sequence recognition and high fidelity (high editing efficiency and low off-target) across a wide range of cell types, hfCas12Max is the newest nuclease member of the type V Cas12 system. Due to hfCas12Max nuclease's smaller size (1080 amino acids) compared to SpCas9 nuclease (1368 amino acids) and LbCas12a nuclease (1228 amino acids), it is easier to package inside lipid nanoparticles (LNPs) or adeno-associated viruses (AAVs).
- 300 pmol ($185)
- Novel CRISPR Nuclease
- Commercial sub-license available
- High Editing Efficiency
- Low Off-Target Editing
- Broad PAM Sequence Recognition While Maintaining High Specificity
- Small Size
- Complex with crRNA without needing tracrRNA
- Excellent CRISPR nuclease for ex vivo and in vivo CRISPR-based Therapies
For CRISPR gene editing, hfCas12Max nuclease is unique in that it can complex with crRNA without the need for a tracrRNA. This means hfCas12Max gRNA length is small, ranging from 44-50 nucleotides (nt) in length, where the target genomic sequence is 17-23 nt long. When complexed with our best-in-class gRNA, hfCas12Max nuclease single RuVC domain will nick the non-target strand and cut the targeted strand in a staggered manner - cleavage predicted 14-16 nt and 24 nt downstream of the PAM site for non-targeted and targeted strand, respectively.